Aurinia is a biopharmaceutical company focused on developing and commercializing therapeutic products. It develops voclosporin, an investigational drug, for the treatment of lupus nephritis and focal segmental glomerulosclerosis. Additionally, the company is advancing voclosporin ophthalmic solution, a topical formulation, for the treatment of dry eye syndrome.